A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Fathima Zumla Cader 1,2, Xihao Hu 3,4,5, Walter L Goh 6, Kirsty Wienand 1,7, Jing Ouyang 1, Elisa Mandato 1, Robert Redd 3, Lee N Lawton 1, Pei-Hsuan Chen 8, Jason L Weirather 8, Ron C J Schackmann 6,9, Bo Li 3 4,10, Wenjiang Ma 1,11, Philippe Armand 1, Scott J Rodig 12, Donna Neuberg 3, X Shirley Liu 13,14, Margaret A Shipp 15; 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 2 AstraZeneca, City House, Cambridge, UK. 3 Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. 4 Harvard T.H. Chan School of Public Health, Boston, MA, USA. 5 GV20 Therapeutics LLC, Cambridge, MA, USA. 6 Department of Cell Biology, Harvard Medical School, Boston, MA, USA. 7 Department of Hematology and Oncology, Göttingen Comprehensive Cancer Center, Göttingen, Germany. 8 Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 9 Merus, Utrecht, the Netherlands. 10 Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA. 11 Clarion Healthcare, Boston, MA, USA. 12 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 13 Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. xsliu@ds.dfci.harvard.edu. 14 Harvard T.H. Chan School of Public Health, Boston, MA, USA. xsliu@ds.dfci.harvard.edu. 15 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Margaret_Shipp@dfci.harvard.edu.